New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
06:06 EDTIMUCImmunoCellular granted orphan drug designation for ICT-107 by EMA
ImmunoCellular Therapeutics announced that the European Medicines Agency, or EMA, has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
09:15 EDTIMUCImmunoCellular to host conference call
President & CEO Gengos discusses the ICT-107 updated data presented at the recently-held Society for Neuro-Oncology's 19th Annual Scientific Meeting on a conference call to be held on November 18 at 5 pm. Webcast Link
November 14, 2014
06:10 EDTIMUCImmunoCellular jpresents positive Phase II data for ICT-107
ImmunoCellular announces the presentation of updated efficacy data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107. Consistent with prior data presentations in December 2013 and June 2014, the results demonstrate a statistically significant progression-free survival benefit, and a numeric overall survival benefit in ICT-107 treated patients compared to the control group. The ICT-107 treatment effect continues to be strongest in the pre-defined HLA-A2 subgroup of patients in which the MGMT methylated patients showed the largest treatment effect, with a significant PFS advantage over the control group, and continued potential for the OS advantage to move toward significance as more events occur. There were no differences in adverse events between the ICT-107 treated group and the control group. The company is utilizing all available information from the controlled phase II trial to design phase III testing in order to increase its probability of success, including the timing of randomization within the standard-of-care treatment these patients receive, in an attempt to limit the number of patients who are "early progressors" and unlikely to respond to therapy.
November 10, 2014
06:03 EDTIMUCImmunoCellular reports Q3 EPS (3c), consensus (6c)

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use